Clik here to view.
PDC*line Pharma Presents First Clinical Results From Phase I/II trial With...
LIÈGE, Belgium & GRENOBLE, France PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, today announces the first...
View ArticleClik here to view.
CANbridge Pharmaceuticals to Participate in Two Investor Conferences in...
BEIJING & CAMBRIDGE, Mass. CANbridge Pharmaceuticals, Inc. (HKEX:1228) , a China and U.S.-based global biopharmaceutical company committed to the research, development and commercialization of...
View ArticleClik here to view.
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) for the...
CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing innovative and affordable oncology...
View ArticleClik here to view.
バイオサイトジェンがTCRミミック抗体を利用した細胞療法の開発に向けたファインイミューンとの協業を発表
中国・北京 & 広州 （ビジネスワイヤ）– バイオサイトジェン・ファーマシューティカルズ（北京）（以下「バイオサイトジェン」、HKEX:...
View ArticleClik here to view.
ImmunoScape Raises $14M to Facilitate the Discovery and Characterization of...
SAN DIEGO & SINGAPORE ImmunoScape, a pre-clinical biotechnology company focused on the discovery and development of next-generation TCR-T-cell therapeutics today announced that it has raised...
View ArticleClik here to view.
Blood Cancer Discovery Publication Further Validates Exscientia’s AI...
VIENNA & OXFORD, England Exscientia (Nasdaq: EXAI), ETH Zurich, the Medical University of Vienna, and the Center for Molecular Medicine (CeMM) today announced a new publication in Blood Cancer...
View ArticleClik here to view.
InnoCare Completes Initial Public Offering on the STAR Market of the Shanghai...
BEIJING InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company for the treatment of cancer and autoimmune diseases, announced today that the Company has successfully got listed on the...
View ArticleClik here to view.
《血癌发现》论文进一步证实，Exscientia的人工智能精准医疗平台可改善患者各项转归指标
维也纳和英格兰牛津 (美国商业资讯)–Exscientia (Nasdaq: EXAI)、苏黎世联邦理工学院、维也纳医科大学和分子医学中心(Center for Molecular Medicine, CeMM)今天宣布，美国癌症研究学会期刊《血癌发现》(Blood Cancer Discovery)新发表了Berend...
View ArticleClik here to view.
CARsgen Presents North America Phase 2 Updates for CT053 BCMA CAR T at the...
SHANGHAI CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces...
View ArticleClik here to view.
BostonGene Showcases Lifesaving Cancer Diagnostic and Treatment...
WALTHAM, Mass. BostonGene announced today that it will participate in the 81st Annual Meeting of the Japanese Cancer Association. The event, to be held at Pacific Convention Plaza Yokohama from...
View ArticleClik here to view.
ネルビアーノ・メディカル・サイエンシズがメルクとの提携およびライセンスオプション契約を発表
伊ネルビアーノ （ビジネスワイヤ） — NMSグループの一員であり、革新的ながん治療薬の創薬と開発を手掛ける臨床段階の企業であるネルビアーノ・メディカル・サイエンシズ（NMS）は本日、高度に選択的で脳透過性がある次世代PARP1阻害剤NMS-293に関するライセンスオプション付きの提携契約をメルク・ヘルスケア（メルク）と締結したと発表しました。...
View ArticleClik here to view.
ブラッド・キャンサー・ディスカバリー誌の論文が患者転帰を改善するエクセンシアのAI精密医療プラットフォームの能力をさらに裏付け
ウィーン & 英オックスフォード （ビジネスワイヤ） — エクセンシア（Nasdaq: EXAI）、スイス連邦工科大学チューリッヒ校、ウィーン医科大学、分子医学研究センター（CeMM）は本日、ベレンド・スナイデル教授の研究室から、「形態学深層学習は画像に基づく生体外薬剤試験による精密医療を強化（Deep Morphology Learning Enhances Precision...
View ArticleClik here to view.
CANbridge Pharmaceuticals Data on CAN106 to be Presented at Two Conferences
BEIJING & CAMBRIDGE, Mass. CANbridge Pharmaceuticals, Inc. (1228.HK), a China and U.S.-based global biopharmaceutical company committed to the research, development and commercialization of...
View ArticleClik here to view.
Nerviano Medical Sciences S.r.l.宣布与默克达成包含许可选择权的合作协议
意大利内尔维亚诺 (美国商业资讯)–Nerviano Medical Sciences S.r.l. (NMS)是NMS集团下属成员公司，也是一家发现和开发癌症创新疗法的临床阶段公司。该公司今天宣布与Merck Healthcare KGaA签署了一项包含许可选择权的合作协议，以开发新一代高选择性和脑渗透性PARP1抑制剂NMS-293。...
View ArticleClik here to view.
Merck’s KEYTRUDA® (pembrolizumab) Receives Four New Approvals in Japan,...
RAHWAY, N.J. Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that KEYTRUDA, Merck’s anti-PD-1 therapy, received four new approvals from Japan’s Ministry of...
View ArticleClik here to view.
Bio-Thera Solutions Announces Enrollment Completed in Phase 1 Study for...
GUANGZHOU, China Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stage biopharmaceutical company, announced today that enrollment for the Phase I clinical study of BAT2022 has been completed,...
View ArticleClik here to view.
Seagen and Zai Lab Announce Regional Strategic Collaboration and License...
BOTHELL, Wash. & SHANGHAI & CAMBRIDGE, Mass. Seagen Inc. (Nasdaq: SGEN), a world leader and pioneer in antibody-drug conjugate (ADC) therapies, and Zai Lab Limited (Nasdaq: ZLAB; HKEX:...
View ArticleClik here to view.
BioJapan2022 |百奥赛图将携创新型新药研发平台、双抗ADC项目和管线进展亮相
中国北京 (美国商业资讯)–百奥赛图（北京）医药科技股份有限公司（“百奥赛图”，股票代码02315.HK）将于10月14日（周五）在BioJapan2022大会举办专题研讨会。研讨会共包括3个报告，将介绍 基于RenMiceTM的五大全人抗体发现平台-基于RenMab®的全人单克隆抗体平台，基于RenLite®的全人双特异性抗体及双抗ADC平台，类TCR抗体平台和GPCR抗体平台...
View ArticleClik here to view.
Biocytogen to Present at BioJapan2022, Introducing Innovative R＆D Platforms,...
BEIJING Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) will host a seminar at the BioJapan2022 Conference on Friday, October 14. The seminar, consisting of 3 modules,...
View ArticleClik here to view.
バイオサイトジェンがBioJapan2022に参加し、革新的な研究開発プラットフォーム、二重特異性ADCプログラム、パイプラインの進捗を紹介へ
北京 （ビジネスワイヤ） — バイオサイトジェン・ファーマシューティカルズ（北京）（以下「バイオサイトジェン」、HKEX: 02315）は、BioJapan2022カンファレンスにおいて、セミナーを10月14日（金曜）に開催します。セミナーは3部構成となり、次の内容を紹介します。...
View Article